Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
271.9 USD | +1.11% | +2.41% | -5.59% |
17.04. | AMGEN INC. : UBS klebt neutral | ZM |
15.04. | AMGEN INC. : TD Cowen bekräftigt seine Kaufempfehlung | ZM |
Kurzporträt
- Arzneimittelverkäufe (94,2%): Medikamente zur Behandlung von Krebs, Stoffwechselstörungen, Knochenerkrankungen, Nierenversagen, Hämophilie usw.;
- Sonstige (5,8%): hauptsächlich Lizenzeinnahmen.
Auf die Vereinigten Staaten entfallen 70,3% des Nettoumsatzes.
Mitarbeiterzahl: 26 700
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8.50% |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15.90% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6.51% |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8.91% |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35.62% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01.06.06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23.10.19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18.12. |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01.01.07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01.01.15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01.01.05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.06.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03.02.17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14.10.16 |
Robert Williams
BRD | Director/Board Member | 75 | 17.10.14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01.01.03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22.07.10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01.06.06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24.10.17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01.01.12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30.07.21 |
Greg Garland
BRD | Director/Board Member | 66 | 16.10.13 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 536 375 548 | 535 025 126 ( 99,75 %) | 0 | 99,75 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
BEIGENE, LTD. 19,82% | 246 269 426 | 19,82% | 2 992 444 422 $ |
NEUMORA THERAPEUTICS, INC. 22,26% | 35 368 653 | 22,26% | 486 318 979 $ |
4 910 000 | 5,50% | 116 121 500 $ | |
VIGIL NEUROSCIENCE, INC. 8,69% | 3 206 281 | 8,69% | 10 933 418 $ |
100 993 | 0,67% | 2 965 154 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the private company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The private company is located in Bermuda. |
Biotechnology
|
Amgen Manufacturing Ltd. (Bermuda)
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-5.59% | 146 Mrd. | |
+25.46% | 659 Mrd. | |
+26.17% | 557 Mrd. | |
-4.86% | 359 Mrd. | |
+16.44% | 322 Mrd. | |
+8.34% | 297 Mrd. | |
+6.28% | 215 Mrd. | |
+7.87% | 210 Mrd. | |
-6.05% | 200 Mrd. | |
-8.79% | 149 Mrd. |
- Börse
- Aktien
- 867900 Aktie
- Unternehmen Amgen Inc.